Background. Malignant pleural mesothelioma (MPM) is a rare, predominantly asbestos-related and biologically highly aggressive tumor associated with a dismal prognosis. Multimodal therapy consisting of platinum-based chemotherapy is the treatment of choice. e reasons underlying the rather poor efficacy of platinum compounds remain largely unknown. Kinase activity might influence cellular response to these regimens. Materials and Methods. For this exploratory study, we screened MPM cell lines (NCI-H2452, NCI-H2052, and MSTO-211H) differing in response to cisplatin and benign control fibroblasts (MRC-5) for overall phosphorylation patterns as well as kinase activity with respect to cellular response to cisplatin-based therapeutics. We analysed the cell lines for cellular kinases in a high-throughput manner using the highly innovative technique PamGene. Cell state analysis including apoptosis, necrosis, and cell viability was performed by using enzyme activity and fluorescent-based assays. Results. Cisplatin alters cellular phosphorylation patterns affecting cell cycle, migration, adhesion, signal transduction, immune modulation, and apoptosis. In cisplatin-responsive cell lines, phosphorylation of AKT1 and GSK3B was decreased but could not be influenced in cisplatin-resistant NCI-H2452 cells. Cisplatin-responsive cell lines showed increased phosphorylation levels of JNK1/2/3 but decreased phosphorylation in cisplatin-resistant NCI-H2452 cells. Conclusion. Kinase phosphorylation and activity might play a crucial role in cellular response to cytostatic agents. Cisplatin influences phosphorylation patterns with distinct features in cisplatin-resistant cells.
Introduction
Malignant pleural mesothelioma (MPM) is a rare, predominantly asbestos-related tumor and associated with a dismal prognosis [1, 2] . In the US, approximately 2500 new cases of mesothelioma are diagnosed each year and the incidence of mesothelioma is expected to decline steadily [1, 3, 4] . In contrast, the incidence of mesothelioma in Europe continues to rise [1, 2, [5] [6] [7] .
Besides pemetrexed, platinum compounds are standard chemotherapeutic agents and still a hallmark of chemotherapy for MPM [8] . In clinical practice, pemetrexed is used in combination with cisplatin [9] or carboplatin [10] [11] [12] [13] . Platinum-containing regimens have a greater activity than nonplatinum containing combinations [14] . Cisplatin treatment shows a response rate of merely 14% and a median survival of fewer than 7 months [15] . Carboplatin treatment results in similar response rates ranging from 6 to 16% [15] . e reasons for this rather poor efficacy of platinum compounds are incompletely understood until now.
Platinum cytotoxicity is based on forming bulky DNA adducts by chemically altering DNA bases by covalent binding of platinum [13] , leading to both DNA interstrand and (1 and 2 or 1 and 3) intrastrand cross-linking [16] [17] [18] [19] [20] [21] [22] [23] . Platinum compounds prevent normal cell replication and trigger apoptosis [18, 22, 24] , unless adducts from genomic DNA are repaired [21] .
Resistance to antitumor agents such as platin compounds has been correlated to a broad spectrum of mechanisms. It is known since the early 1990s that the activity of several proteins involved in the development of antitumor drug resistance is regulated by protein phosphorylation [25] . Especially, the role of protein kinase C and others has been previously described [26] . During the past decade, our understanding of the underlying effect of platin-induced apoptosis has increased greatly by the identification of some of the major components involved in apoptosis and the processes regulating their activation. Kinases that have been suggested to play a role in apoptosis encompass the mitogen-activated protein kinase (MAPK) family, specifically p42/44 ERK, p38 MAPK, c-Jun N-terminal kinase (JNK), cyclic AMP-dependent protein kinase (PKA), protein kinase B (PKB), or AKT and protein kinase C (PKC) [27] . Furthermore, phosphorylation levels of different DNA damage genes such as ATM or ATR are known to influence cellular response to replicative stress induced by platinum containing drugs [28] . In addition, it has been shown in ovarian cancer and sarcoma cells expressing constitutively active JAK2 that cisplatin significantly inhibited tyrosine phosphorylation and kinase activity of JAK2 in a dose-and time-dependent manner [29] .
Against this background, we aimed to investigate the impact of overall phosphorylation patterns as well as kinase activity in cellular response to cisplatin-based therapeutics.
erefore, we analysed different MPM cell lines for cellular kinases in a high-throughput manner using the highly innovative technique PamGene.
Materials and Methods

Cell Culture. MPM cell lines MSTO-211H
(biphasic subtype and moderately cisplatin sensitive) and NCI-H2052 (epithelioid subtype and cisplatin sensitive) as well as the cell line NCI-H2452 (sarcomatoid subtype and cisplatin-resistant) were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium ( ermo Fisher Scientific, Massachusetts, USA). e human lung-fibroblast cell line MRC-5 was used as a control cell line. MRC-5 cells were cultured in Minimal Essential Medium ( ermo Fisher Scientific). All culture media were supplemented with 10% fetal calf serum and 1% penicillin and streptomycin ( ermo Fisher Scientific).
Treatment of MPM Cell Lines with Cisplatin.
e effect of cisplatin on kinase activity was analysed in each cell line.
erefore, 1.6 × 10 5 cells/well were seeded in a 24-well plate. After 12 h of incubation at 37°C and 5% CO 2 , 10 μM of cisplatin (Selleckchem, Houston, USA) was added to cells. After 48 h of incubation with cisplatin, protein isolation was performed according to the protocol 1160 from the PamGene platform (PamGene International B. V., Wolvenhoek, Netherlands). erefore, cells were lysed by using M-PER Mammalian Protein Extraction Reagent containing HALT phosphatase inhibitor cocktail and HALT protease inhibitor cocktail EDTA-free ( ermo Fisher Scientific). Lysed cells were harvested by using a cell scraper. Lysates were stored in 5-20 μl aliquots at − 80°C.
e protein concentration was determined via fluorometric quantification (Qubit, ermo Fisher Scientific) using the protein assay kit according to the manufacturers' instructions.
Protein Tyrosine Kinase Assay.
e Protein Tyrosine Kinase Assay (PTK Assay, PamGene) was performed according to the manufacturers' instructions. e PamChip ® -4 was prepared by a blocking step with 30 μl of 2% BSA (PamGene). Master mix was prepared by using the reagent kit for PTK PamChip arrays (PamGene). 5 μg of sample protein lysate was applied. As required for the mastermix, ATP (4 mM) was diluted 1 : 25.
Serine/ reonine Kinase Assay.
e Serine/ reonine Kinase Assay (STK Assay, PamGene) was performed according to the manufacturers' instructions. e PamChip ® -4 was prepared by a blocking step with 30 μl of 2% BSA (PamGene). Master mix was prepared by using the reagent kit for STK PamChip arrays (PamGene). 0.5 μg of sample protein lysate was applied. As required for the mastermix, ATP (4 mM) was diluted 1 : 25.
Kinase Activity Determination.
Analysis of the results of PTK and STK assay was performed by using the BioNavigator software (PamGene).
Image analysis and log2 transformation of the results were performed by using the BioNavigator software 2
Journal of Oncology (PamGene). Based on substrate phosphorylation pattern, kinase activities of each specific kinase were estimated using the kinase upstream analysis algorithm (BioNavigator). Each corresponding kinase was classified by specificity of each kinase, and dependency power levels were calculated. To visualize kinase activity changes before and after cisplatin treatment, kinase trees were generated by using the KinHub platform (http://www.kinhub.org/kinmap/). 
Results
Cisplatin Treatment Reveals Differences in Phosphoryla-
tion Pattern. MRC-5 cells showed minor changes in phosphorylation of phosphosites when comparing cisplatin treatment (highlighted by black bars) and medium (highlighted by grey bars) ( Figure 1 , green bars). MSTO-211H cells (blue bars) presented with changes in phosphorylation during cisplatin therapy. MSTO-211H has a distinct cluster in its phosphorylation pattern compared to the other MPM cell lines. During therapy, a similar shift in the phosphorylation pattern could be observed compared to the other two MPM cell lines. Untreated, a similar phosphorylation pattern could be detected for MSTO-211H cells. However, certain phosphosites showed a significantly enhanced signal. NCI-H2052 (red bars) and NCI-H2452 (yellow bars) presented with an overlap in their phosphorylation pattern and showed a much stronger phosphorylation of multiple phosphosites without exposition to cisplatin. MRC-5 presented in general with minor phosphorylation regardless of the respective phosphosites and treatment.
In sum, 54 phosphosites showed significantly altered phosphorylation during cisplatin therapy. 52 showed a reduction in phosphorylation status due to treatment, whereas two (PPR1A and FOXO3) showed an induction in their phosphorylation. In Figure 2 , ten phosphosites with the most significant changes in phosphorylation after treatment with cisplatin are shown (p values are shown in Suppl. Table 1 ). A significant global reduction of tyrosine phosphosite phosphorylation could be outlined. No biologically relevant significance for serine/threonine kinases was monitored.
e comparison of significantly altered phosphorylation levels between the different cell lines revealed 62 alterations.
e majority of differences [29] could be observed between MSTO-211H and the MRC-5 control cell line (Suppl. Table 2). In line with the results visualized in the heatmap, all targets showed significantly reduced signals. Between NCI-H2452 and MRC-5, 15 differences were observed, again, all with lower phosphorylation levels. Also, between NCI-H2052 and MRC-5, ten significantly higher phosphorylated sites could be observed in the tumor cells. Between MSTO-211H and NCI-H2452, three phosphosites (CD3Z, EGFR, and GSK3ß) showed a higher phosphorylation and four phosphosites (EFS, ENOG, EPHA7, and PTN6) showed lower phosphorylation levels in NCI-H2452 cells. Between NCI-H2052 vs. MSTO-211H, as well as between NCI-H2052 vs. NCI-H2452, no significantly altered phosphorylation levels could be observed.
Influence of Different Phosphorylation Patterns in
Response to Cisplatin. Overall, high phosphorylation of phosphosites (Suppl. Table 3 ) lead to resistance against cisplatin therapy. In general, 24 phosphosites seem to impact cellular response to cisplatin-based therapeutic regimens. Respective phosphosites are shown in Suppl. Table 3 . Especially, high phosphorylation of ESR1, LAT, PTN12, and PTN6 showed the strongest apoptosis-preventing effect. e circos plot ( Figure 3 ) depicts the frequency of high or low phosphorylated phosphosites of kinases and their responsiveness to cisplatin.
Biological Relevance and Effected Cellular Pathways.
Analysis of the phosphorylation pattern with respect to MAPK signaling pathway (KEGG hsa04010), cell cycle (KEGG hsa04110), and pathways in cancer (KEGG hsa05200) was performed for each cell line. Induction of phosphorylation by cisplatin is indicated by green labels, and reduction of phosphorylation is indicated in red labels (Suppl. Figures 1-3 ). In the MAPK signaling pathway, cisplatin reduces phosphorylation of receptor tyrosine kinases (especially EGFR, EPHA2, and KDR), and RASA1, RAF1, and AKT1 in each cell line. In the cell cycle pathway, GSK3B, CDK2, and CDK1 are reduced by cisplatin in each cell line, and in cancer pathways, cisplatin reduces phosphorylation of GSK3B, AKT1, PDGFRa/b, PLCG1/2, and CDK2. In NCI-H2452 cells, the reduction of phosphorylation by cisplatin is weaker than in other cell lines (indicated by light red).
Proteins contributing to cell adhesion/migration and membrane properties showed a cluster with remarkable response to cisplatin treatment in NCI-H2052 and MSTO-211H. EPHA1 (Suppl. Figure 4B ), EPHA2 (Suppl. TEC  TYK2  ARAF  JAK3  LAT  MET  GSK3B  BTLA  PRRX2  TYRO3  PTK2B  RAF1  KIT  CD3E  EPOR  FER  EPHA7  PDPK1  PTPN6.1  EPHA1  EPHA2  EPB41  MPZL1  RASA1  CDK2  HAVCR2  PXN  PTPN11  ZAP70  FRK  PLCG2  PTPN6  PECAM1.1  PLCG1  15  13  14  18  17  16  19  21  20  24  22  23  7  9  3  1  2  6  4  5  10 Figure 2: Top 10 influenced phosphosites during cisplatin therapy. On the y-axis, phosphosites of the respective protein are shown. Each box summarizes the results for all four cell lines, being measured in triplicates (dark blue � medium and light blue � cisplatin). To make the results comparable, the x-axis depicts a dimensionless Z-score. A significant, global reduction of tyrosine phosphosite phosphorylation could be observed. No significance for serine/threonine kinases was monitored. e figure focusses on the top 10 changes because further boxplots would be repetitive. In sum, 77 phosphosites showed significantly altered phosphorylation during cisplatin therapy. p values are depicted in Suppl. Table 1 . Journal of Oncology Figure 4C ), EPHA7 (Suppl. Figure 4D) , EFS (Suppl. Figure 6B ), EPB41, PTK2B (Suppl. Figure 6D) , FER, FES, KIT (Suppl. Figure 5A) , PXN, PECAM1, PDGFRB, KDR (Suppl. Figure 6A) , and ZAP70 showed comparable phosphorylation changes during cisplatin therapy (all p < 0.01 after Bonferroni correction; Table 1 ). Phosphorylation of the PTK phosphosites was low in fibroblasts in general. In NCI-H2452, cisplatin therapy led to a low reduction of phosphorylation with respect to the mentioned proteins. Instead, NCI-H2052 showed a much stronger reduction of phosphorylation of the mentioned phosphosites. MSTO-211H showed an intermediate to strong response during cisplatin therapy with respect to reduction of phosphorylation. Cisplatin therapy led to major changes in EFS phosphorylation, as phosphorylation decreased in all cell lines in a remarkable manner (p < 0.0001). In MRC-5 cells, the phosphosite was not anymore phosphorylated during cisplatin treatment. e result for EFS is shown in Suppl. Figure 6B . Cisplatin leads to a reduction of AKT1 phosphorylation influencing one of the three AKT1 phosphosites (Suppl. Figure 6C ). Phosphorylation was low in MRC-5 cells, regardless of the treatment. NCI-H2052 showed the strongest changes in AKT1 phosphorylation during therapy. Similar results were found for PTK2B (Suppl. Figure 6D) , which is an upstream regulator of AKT1. Phosphorylation reduced during cisplatin therapy in NCI-H2052 and MSTO-211H, whereas the other cell lines showed minor response. PDGFRB and KDR phosphorylation showed comparable phosphorylation changes as mentioned above. Both contribute to the activation of AKT1.
Additional proteins that mediate inter-and intracellular signal transduction (ARAF, EPHA1, EPHA2, EPHA7, KIT, PTPN11, PIK3R1, PTPN6, and KDR) showed similar results as depicted in Suppl. Figures 4-6 .
e changes in phosphorylation are redundant to the results mentioned before.
BTLA, CD3E, CD247, CD79A, PTK2B, HAVCR2, PECAM1, and ZAP70 modulate immune response and showed differential phosphorylation during therapy. NCI-H2052 showed the strongest decrease in phosphorylation of these proteins during cisplatin therapy. In addition, phosphorylation was much higher before therapy compared to the other cell lines investigated. Similar high phosphorylation was also found in NCI-H2452 before therapy, but phosphorylation reduced less during therapy compared to NCI-H2052. Phosphorylation in MSTO-211H was much lower compared to the other two MPM cell lines. During therapy, only a minor reduction of phosphorylation was monitored for proteins modulating immune response. MRC-5 phosphorylation was low in general but decreased during therapy to a nonmeasurable extent.
Phosphorylation of proteins driving cell cycle control showed major changes during therapy (CDK1, CDK2, EPHA1, EPHA2, EPHA7, ENO2, PTK2B, FER, FES, FRK, KIT, PDGFRB, and KDR). e changes were similar to the above presented results. Again, NCI-H2052 showed the strongest changes, followed by NCI-H2452. Similar, but with general lower phosphorylation, MSTO-211H was comparable with the other two MPM cell lines. Again, MRC-5 presented with generally low phosphorylation of the reported proteins and reduced during therapy-in most cases, phosphorylation was absent due to cisplatin treatment.
Upstream Kinase Analysis.
Kinase trees were created for each cell line (Suppl. Figures 9A-9D ).
e most affected kinases were in the family of tyrosine kinases (e.g., ALK, FES, and ZAP70) and CMGC kinases (e.g., CDK1, CDK2, and ERK1) in all four cell lines.
As depicted in the score plots and volcano plots (Suppl. Figures 7-8) , NCI-H2052 cells showed a 2.5-3-fold decrease in kinase activity of FGFR1, FES, and ALK due to cisplatin treatment, with a high specificity score (2, dark red) for the respective phosphosites. In NCI-H2052, as well as in MRC-5 cells, kinase activity of ERK1/2 and CDK1 was 2.3-fold increased due to cisplatin treatment. In MRC-5 cells, kinase activity of HER2, FLT3, and EGFR showed a very strong decrease (6-9.5-fold) with a high specificity (2, dark red) for ten respective phosphosites. In MSTO-211H cells, kinase activity was decreased (3-4-fold) by 10 phosphosites with high specificity. Kinase activity was slightly decreased (0.4-0.7-fold) in NCI-H2452 for FAK1, Ron, SRC, CK1, and COT.
Discussion
Platinum compounds are standard chemotherapeutic agents and still a hallmark of chemotherapy for MPM in combination with pemetrexed [30] . Nevertheless, platin-containing regimens show unsatisfying response.
erefore, we investigated MPM cell lines, differing in their response to cisplatin (NCI-H2052: high apoptotic response, MSTO-211H: sparsely apoptotic response, and NCI-H2452: no response). We screened the cells for overall phosphorylation patterns as well as kinase activity with respect to cellular response to cisplatin-based therapeutics. We analysed the cell lines for cellular kinases in a high-throughput manner using the highly innovative technique PamGene.
In our study, we could demonstrate differences in the phosphorylation pattern in all cell lines due to cisplatin treatment. Overall, increase in phosphorylation after addition of cisplatin indicate an adaptive mechanism to escape from the effect of cisplatin. In particular, high phosphorylation of ESR1, LAT, PTN12, and PTN6 showed antiapoptotic effects. PTN12 has dephosphorylation functions and therefore influences cellular signaling cascades [31] . It dephosphorylates cellular tyrosine kinases like ERBB2 and PTK2B. ERBB2 encodes HER2/neu that inhibits apoptosis by stimulation of proliferation via the RAS-MAP kinase pathway [32, 33] . In NCI-H2452 cells, phosphorylation levels of ERBB2 is not reduced, compared to other cell lines.
erefore, it could be suggested that this mechanism plays a role in this cell line, supporting its cisplatin resistance.
BTLA, CD3E, CD247, CD79A, PTK2B, HAVCR2, PECAM1, and ZAP70 modulate immune response and showed differential phosphorylation during therapy. e activation of BTLA leads to inhibition of CD8 + cancerspecific T-cells [34] . BTLA showed decreased 6
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Protein tyrosine kinase 2 beta (EC 2.7.10.2) (focal adhesion kinase 2) (FADK 2) (proline-rich tyrosine kinase 2) (cell adhesion kinase beta) (CAK beta) (calciumdependent tyrosine kinase) (CADTK) (related adhesion focal tyrosine kinase) (RAFTK)_FAK2_572_584_Q14289 Erythropoietin receptor precursor (EPO-R)_EPOR_361_373_P19235 4.82E − 07 4.29E − 05 1-Phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 (EC:3.1.4.11) (phosphoinositide phospholipase C-gamma-2) (PLC-IV) (phospholipase C-gamma-2) (PLC-gamma-2)_PLCG2_1191_1203_C1200S_P16885 Gao et al. found that elevated expression and phosphorylation of AKT by GSK3B and PTEN was correlated with cell viability, migration, and apoptosis, and this might be explained by chemoresistance in breast cancer [35] . In NCI-H2052, we could reduce phosphorylation of AKT1 and GSK3B by cisplatin and therefore could induce apoptosis in this cell line. Cisplatin-treated and untreated NCI-H2452 cells showed no significant changes between phosphorylation of AKT1. Benzothienopyrimidine derivative (BIA-6), an AKT inhibitor, could effectively block the PI3K/AKT pathway in lung cancer cells in a dose-dependent manner and thus increase apoptosis [36] . Based on our data, a possible synergistic effect with platin-based treatment can be suggested. It could be possible that BIA-6 might also improve efficiency of cisplatin in NCI-H2452 cells.
In NCI-H2052, as well as in MRC-5 cells, kinase activity of p38 and ERK1/2 was increased due to cisplatin treatment. Hsieh et al. also assessed increased phosphorylation of ERK1/2 and p38 in nasopharyngeal carcinoma (NPC) and observed this effect by activation of caspases [37] . is confirms to our observation since NCI-H2052 and MRC-5 showed the highest apoptotic response to cisplatin. MSTO-211H, with lower apoptosis rates, showed only a slight increase of activity of p38 and ERK1/2, whereas nonresponding NCI-H2452 cells showed decreased p38 kinase activity.
Zhao et al. observed associations between increased apoptosis by high expression of phosphorylated c-Jun N-terminal kinase (JNK) and subsequently elevated expression levels of p53 in ovarian cancer cells during treatment of platinum containing drugs [38] . is supports our observation in NCI-H2052 and MRC-5, showing elevated activity of JNK1/2/3 and decreased phosphorylation of JNK1/3 in cisplatin-resistant NCI-H2452 cells. Bar et al. found the activating transcription factor 3 (ATF3) as an important regulator of cisplatin cytotoxicity, being activated in platin-sensitive lung cancer cells due to cisplatin treatment [39] . In platin-sensitive cells, cisplatin induced activation of JNK and thus ATF3 induction. In their tested resistant cell lines, this JNK induction was missed. In their study, they tested the FDA-approved histone deacetylase inhibitor vorinostat demonstrating synergistic cytotoxicity in lung cancer cell lines Calu-6 and NCI-H23 cells together with cisplatin. As NCI-H2452 cells also show still activity of JNK, it would be interesting to test this histone deacetylase inhibitor also in this cell line.
Conclusions
Kinase phosphorylation and activity might play a crucial role in cellular response to cytostatic agents. Cisplatin treatment results in altered phosphorylation patterns in both the MPM cell lines and the lung fibroblast cell line. ese alterations have consequences for cell cycle, migration, adhesion, signal transduction, immune modulation, and apoptosis of the cell. Cisplatin-resistant MPM cells showed a clearly distinct phosphorylation pattern compared to cells showing response to cisplatin, indicating a specific sensitivity-profile. Our results indicate that inhibition of AKT1 by, e.g., BIA-6, or, in another approach, induction of p38 or JNK1/3 of the MAPK pathway, might offer positive synergistic effects through induction of an apoptotic response to cisplatinbased treatment and thus potentially enhance patients' clinical outcome.
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